CHEST 2024 Key Takeaways: Innovations in IPF and PAH

home / post-conference-perspectives / chest-2024-key-takeaways-innovations-in-ipf-and-pah

Steven Nathan, MD, discusses how key findings from CHEST 2024, including survival predictors from the IPF-PRO Registry and the potential of inhaled treprostinil for CTD-PAH, are shaping new approaches to managing IPF and PAH, with a focus on early diagnosis, personalized treatments, and improving patient outcomes.

Episodes

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo